Glimepirida Generis

Glimepirida Generis is a prescription oral medication that contains the sulfonylurea active ingredient glimepiride. It is supplied in tablet form, with the specific strength not disclosed, and is marketed within the European Union. The product is intended for use under medical supervision to help manage blood glucose levels in adults with type 2 diabetes mellitus.

Glimepirida Generis is indicated for the management of type 2 diabetes mellitus as part of a comprehensive treatment plan that includes diet and exercise. It may be used when lifestyle measures alone are insufficient to achieve glycemic control.

- Adjunct therapy for adults with type 2 diabetes mellitus. - Used when metformin or other oral agents do not achieve target glucose levels. - Can be combined with other antidiabetic drugs, such as metformin, under physician guidance. - May be prescribed for patients who require additional insulin secretagogue effect. - Intended for long‑term glycemic management in conjunction with lifestyle modifications.

Glimepirida Generis may cause a range of side effects, some of which are more frequently observed while others are less common but potentially serious.

Common: - Mild to moderate hypoglycemia (low blood sugar). - Weight gain. - Nausea or gastrointestinal discomfort. - Headache. - Dizziness or light‑headedness. - Fatigue.

Serious: - Severe hypoglycemia requiring medical attention. - Allergic reactions such as rash, itching, or swelling. - Liver function abnormalities. - Blood dyscrasias (e.g., leukopenia, thrombocytopenia). - Acute pancreatitis. - Cardiovascular events in susceptible individuals.

Before starting Glimepirida Generis, certain health considerations should be reviewed to minimize risks and ensure safe use.

- Assess renal and hepatic function; dose adjustment may be needed in impairment. - Use cautiously in elderly patients due to increased hypoglycemia risk. - Pregnancy and lactation status are not well established; avoid use unless clearly indicated. - Monitor blood glucose regularly to detect hypoglycemia early. - Advise patients to limit alcohol intake, which can potentiate hypoglycemia. - Evaluate cardiovascular status, as sulfonylureas may affect heart disease patients. - Review concomitant medications that may influence glucose levels.

Glimepirida Generis can interact with several drug classes, affecting its efficacy or safety profile.

Avoid: - Other sulfonylureas or meglitinides (additive hypoglycemia risk). - MAO inhibitors (potential for severe hypoglycemia). - Certain antibiotics such as fluoroquinolones and macrolides (enhanced hypoglycemic effect). - High‑dose salicylates (may increase insulin secretion).

Use with caution: - Beta‑blockers (may mask hypoglycemia symptoms). - Thiazide diuretics (can raise blood glucose). - ACE inhibitors and ARBs (monitor renal function and potassium). - NSAIDs (possible renal impairment affecting drug clearance). - Oral contraceptives (may alter plasma drug levels).